Diabetes
From the Journals
Fewer than 10% of eligible type 2 diabetes patients get new, pricey drugs
Only 9% of eligible adults with T2D received treatment with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020, in a new analysis.
Opinion
Toxic chemicals we consume without knowing it
“A grossly underappreciated driver in what ails us is the role of environmental toxins and endocrine-disrupting chemicals.”
From the Journals
Irregular sleep tied to markers of atherosclerosis
‘Poor sleep is linked with several cardiovascular conditions.’
Conference Coverage
Therapy app cut A1c, drug intensification in T2D
Livin' on the MDedge
A purple warrior rises in the battle against diabetes
Plus: Rare honey builds strong but bacteria-prone bone implants, and mycoprotein builds strong gut microbiomes.
Feature
How to get started with prescribing and advising on CGM
Continuous glucose monitoring is gaining ground with both patients and providers because of an array of driving forces.
From the Journals
Diabetes drug tied to lower dementia risk
Risk for dementia is doubled in adults with T2DM, say the authors of a new paper.
From the Journals
COVID-19 shot appears to reduce diabetes risk, even after Omicron
Several studies conducted early in the pandemic suggested increased risks for both new-onset diabetes and cardiometabolic diseases following COVID...
From the Journals
Type 1 diabetes no longer a disease of the thin: Lifestyle advice needed
The prevalence of overweight/obesity was similar for people with type 1 diabetes and those without diabetes in a nationwide survey.
Feature
Dapagliflozin gets expanded heart failure indication in Europe
The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction.
From the Journals
Longer life after bariatric surgery, but suicide risk in young
Death from diabetes was 72% lower in the bariatric surgery patients versus nonsurgery peers.